Planning Zigbee Network For Monitoring Application

ZigBee is the new wireless technology developed by ZigBee Alliance and guided by IEEE 802.15.4 Personal Area Network standard to overcome the limitations of Bluetooth and Wi-Fi. It’s envisioned for wide range of applications. ZigBee nodes are self-organized and have the ability to communicate with each other and to collaborate to achieve the goals of the network

Relationship Between Serum Testosterone, Leptin,Interleukin-6 (il-6) Level and Insulin Sensitivity in Non-obese and Obese Male Subjects in Magway Region, Myanmar

Objective: To determine the relationship between insulin resistance and related variables (serum testosterone, interleukin (IL-6) and leptin level) in obese and non-obese healthy subjects. Methods: Community-based crosssectional, analytic study was undertaken in 60 subjects for each obese group (BMI ≥ 30.0 kg/m2) and non-obese group (BMI 18.5 to 24.9 kg/m2) (age;18-45 years) residing in Magway Township from December 2016 to December 2017. Serum insulin, testosterone, IL-6 and leptin levels were measured by enzyme linked immunoassay, and serum fasting glucose was measured by glucose oxidase method. Insulin sensitivity was calculated by HOMA formula (Homeostatic Model Assessment). Results:HOMA-IR, serum leptin and IL-6 level were significantly higher in obese group while serum testosterone level was significantly lower in obese group. There was a significantly correlation between HOMA-IR with leptin (r=0.306, p=0.001), IL-6 (r=0.237, p=0.009) and testosterone (r=-0.209,p=0.02). Moreover, serum leptin was significantly and positively correlated with IL-6 (r=0.391, p<0.001) while serum testosterone was significantly and negatively correlated with leptin (r=-0.408, p<0.001), and IL-6 (r=-0.34, p<0.001).Conclusions:Obese men are more likely to have low testosterone, high inflammatory markers leptin and Il-6, which were associated with decreased insulin sensitivity.

Adverse Drug Reactions in Selected Wards of the Yangon General Hospital and Yangon Specialty Hospital During the First Quarter of 2019 : An Active Pharmacovigilance Study in Myanmar

Previous studies in Europe and the USA have reported a high prevalence of adverse drug reactions (ADRs), but data on local ADRs in Myanmar are sparse. Our objective was to study ADRs in patients admitted to selected wards of Yangon General Hospital (YGH) and Yangon Specialty Hospital (YSH), Myanmar. This was a prospective observational study in three hospital wards during the first quarter of 2019. Suspected ADRs were carefully investigated in a face-to-face interview with each patient and via review of clinical records. Patients transferred to other wards or discharged were followed-up by the researchers until day 28 after admission. ADRs were divided into those that (1) led to the admission and (2) occurred during the hospital stay or after discharge (up to day 28 after admission). A total of 65 ADRs were identified, with 47 (29.4%) of 160 patients experiencing at least one ADR. Among these, 16 (24.6%) had led to hospital admission and 49 (75.4%) occurred in 31 patients during their hospital stay. Of 160 patients, 21 had taken at least one herbal remedy and six of these developed an ADR. Five ADR-drug associations (hypokalaemia with methylprednisolone, increased transaminase levels with standard antituberculosis drugs, upper gastrointestinal bleeding with nonsteroidal anti-inflammatory drugs, constipation with tramadol, and increased transaminase levels with herbal remedies) represented 18 (27.7%) of the 65 ADRs in this study. According to the Schumock and Thornton preventability scale, more than half of these ADRs (35 [53.9%]) were preventable. The present study highlights the existence of ADRs among patients attending these hospitals. The implementation of active pharmacovigilance in hospitals could be a helpful first step to improving the awareness of unwanted effects of medicines and patient safety, as well as a way to strengthen the national pharmacovigilance system in countries such as Myanmar. The online version of this article (10.1007/s40801-020-00180-0) contains supplementary material, which is available to authorized users